Posaconazole

Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity.

Product Specifications

CAS Number

[171228-49-2]

Product Name Alternative

SCH 56592

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Fungal; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Posaconazole.html

Purity

99.95

Solubility

DMSO : 18.75 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=C([C@@]2(CN3C=NC=N3)C[C@H](COC4=CC=C(N5CCN(C6=CC=C(N7C=NN([C@@H](CC)[C@H](C)O)C7=O)C=C6)CC5)C=C4)CO2)C(F)=C1

Molecular Formula

C37H42F2N8O4

Molecular Weight

700.78

Precautions

H302, H315, H319, H335

References & Citations

[1]Benaim G, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2006 Feb 9;49 (3) :892-9.|[2]Sabatelli F, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006 Jun;50 (6) :2009-15.|[3]Sansone-Parsons A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006 May;50 (5) :1881-3.|[4]Veiga-Santos P, et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2012 Jul;40 (1) :61-71.|[5]Sun QN, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002 Jul;46 (7) :2310-2.